Abstract: Use of an autologous e.g., selected, renal cell therapeutic for improving kidney function of a human patient having diabetic chronic kidney disease is provided herein. The use of the therapeutic, administered in first and second injections, increases patient kidney function. e.g., estimated glomerular filtration rate, over the course of at least one year and stabilizes other clinical parameters that decline during kidney disease.

Abstract: The present invention concerns bioactive renal cell populations, renal cell constructs, and methods of making and using the same.

Abstract: The present invention concerns bioactive renal cell populations, renal cell constructs, and methods of making and using the same.

Abstract: This disclosure provides an autonomous machine system having a scheduling controller configured to determine one or more windows of availability over a time period when the autonomous machine is allowed to operate to perform one or more operational tasks; determine a total operation time over the time period; and determine an operating schedule for a work region that assigns one or more operational tasks to the one or more windows of availability based on the total operation time. The autonomous machine may be commanded to operate in the work region according to the operating schedule.

Abstract: The present invention concerns methods of using bioactive renal cell populations to provide regenerative effects to a native kidney for the treatment of chronic kidney disease.

Abstract: Provided herein are, inter alia, devices, methods, and systems are provided for delivering pharmaceutical fluid formulations, such as with metered infusion capabilities delivered extravascularly to target locations within a patient while maintaining positional stability. An exemplary device can be configured to deliver non-continuous streams or boluses of fluid to a target site. In certain embodiments, the injection device can engage with an exemplary trocar that is configured to have one or more stabilization mechanisms on a shaft thereof such that the trocar provides a stable delivery mechanism to the injection device. The trocar is configured to receive an injection needle therein that is attached to the injection device, and the injection device can deliver fluid therethrough to a target tissue site.

Abstract: The invention is directed to isolated renal cells, including tubular and erythropoietin (EPO)-producing kidney cell populations, and methods of isolating and culturing the same, as well as methods of treating a subject in need with the cell populations.

Abstract: The present invention concerns methods of using bioactive renal cell populations to provide regenerative effects to a native kidney for the treatment of chronic kidney disease.

Abstract: Methods of identifying an enriched heterogeneous renal cell population having therapeutic potential, enriched heterogeneous renal cell populations having therapeutic potential and uses for same.

Abstract: Provided herein arm, inter alia, methods, cell populations, and compositions for treating chronic kidney disease in subjects with a congenital anomaly of a kidney and/or urinary tract.

Abstract: This disclosure provides an autonomous machine system having a scheduling controller configured to determine one or more windows of availability over a time period when the autonomous machine is allowed to operate to perform one or more operational tasks; determine a total operation time over the time period; and determine an operating schedule for a work region that assigns one or more operational tasks to the one or more windows of availability based on the total operation time. The autonomous machine may be commanded to operate in the work region according to the operating schedule.

Abstract: The present invention concerns methods of using bioactive renal cell populations to provide regenerative effects to a native kidney for the treatment of chronic kidney disease.

Abstract: Provided herein are, inter alia, extracellular products (e.g., vesicles such as microvesicles, e.g., exosomes) produced by renal cells (such as bioactive renal cells, e.g., selected renal cells). Methods of altering components (such as miRNAs or proteins) of vesicles produced by cells, as well as methods of producing vesicles comprising various compounds are also included.

Abstract: The present invention concerns methods of using bioactive renal cell populations to provide regenerative effects to a native kidney for the treatment of chronic kidney disease.

Abstract: The present invention concerns methods of using bioactive renal cell populations to provide regenerative effects to a native kidney for the treatment of chronic kidney disease.

Abstract: The present invention concerns bioactive renal cell populations, renal cell constructs, and methods of making and using the same.

Abstract: The present invention concerns bioactive renal cells populations, renal cell constructs, and methods of making and using the same.

Abstract: Provided herein are, inter alia, therapeutic formulations containing active agents, such as bioactive cell populations, and methods of making and using the same.

Abstract: Provided herein are, inter alia, compositions and methods for using genetically modified bioactive renal cell populations to provide regenerative effects to a native kidney for the treatment of chronic kidney disease. In certain embodiments, the aim is to effectively provide a “universal donor” immune-privileged renal cell population where gene editing is used to generate a modified allogeneic renal cell population to be administered to patients without immunosuppression.

Abstract: The invention is directed to isolated renal cells, including tubular and erythropoietin (EPO)-producing kidney cell populations, and methods of isolating and culturing the same, as well as methods of treating a subject in need with the cell populations.